Your Article Summary
See Latest ArticlesEffects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
The Prostate, 06/30/09
Festuccia C et al. - In a study to determine why EGFR inhibitors been so ineffective in human prostate cancer (PCa), the results seem to suggest that a low EGFR/Her2 ratio and PTEN absence are the main factors responsible of erlotinib inefficacy. The inhibition of EGFR could have important antitumor effects in hormone-naive rather than in hormonally treated pts.
Methods- The effectiveness of erlotinib was assessed in a wide range of PCa cells (wild type or engineered to overexpress peculiar proteins including androgen receptor and PTEN).
- The effectiveness of erlotinib was inversely correlated to the EGFR/Her2 ratio rather than EGFR/p-EGFR or Her2/p-Her2 levels.
- Chronic treatment with bicalutamide induced overexpression of Her2 and reduction of EGFR/Her2 ratio and this was associated with increased Akt and Erk activity.
- In these treatment conditions, a reduced efficacy of erlotinib was observed.
- At the same time, an increased efficacy vs erlotinib was documented in cancer cells chronically exposed to DHT.
- In these culture conditions, low levels of Her2 and increased EGFR/Her2 ratio were evidenced.
Related Articles
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Lung Cancer, 10/07/09
Relevance Score: 87%
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09
Relevance Score: 85%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 85%
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09
Relevance Score: 83%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/18/09
Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 12/18/09
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/18/09
Patient Perceived Effectiveness of a New Male Sling as Treatment for Post-Prostatectomy Incontinence
The Journal of Urology, 12/18/09
Health-related quality of life in men with localized prostate cancer
International Journal of Urology, 12/18/09